GO
Loading...

Biotechnology

More

  • Biotech earnings: All eyes on Gilead     Tuesday, 22 Apr 2014 | 3:45 PM ET

    CNBC's Meg Tirrell previews the earnings of biotech players Gilead and Amgen. Tirrell explains why investors will be focusing on Gilead's Sovaldi sales.

  • Biggest biotech players     Tuesday, 22 Apr 2014 | 1:07 PM ET

    CNBC's Dominic Chu provides the big picture on some of the biggest players in biotech.

  • Focus on large-cap, diversified biotech: Pro     Monday, 21 Apr 2014 | 2:09 PM ET

    Discussing the pullback in biotech, with Paul Hickey, Bespoke Investment Group.

  • Love biotech on correction: Trader     Tuesday, 15 Apr 2014 | 12:40 PM ET

    The FMHR traders debate the play on large cap versus small cap biotech stocks.

  • Top biotech analyst forecasts bottom     Tuesday, 15 Apr 2014 | 12:37 PM ET

    Discussing large cap versus small cap biotech stocks, and the hottest picks in the space, with Yaron Werber of Citi.

  • NEW YORK, April 13- The wrenching selloff in U.S. high-growth technology and biotech shares could leave investors braced for more than a minor pullback when earnings pick up speed this week.

  • Europe shares sag as U.S. tech sector sell-off spreads Friday, 11 Apr 2014 | 11:00 AM ET

    PARIS, April 11- European stocks sank on Friday, extending the week's retreat and mirroring a sell-off on Wall Street led by technology and biotech shares that has been fuelled by worries some stock valuations are overstretched.

  • Here's what's pushing biotech lower: Expert     Friday, 11 Apr 2014 | 8:42 AM ET

    I think a lot of it had to do with pricing concerns over Gilead's Sovaldi, says Jason Kolbert, Maxim Group, sharing his thoughts on the future of the biotech sector and pending IPOs.

  • Studies: Lab-grown nostrils, vaginas working well Friday, 11 Apr 2014 | 4:25 AM ET

    LONDON— Two new studies describe the latest achievements in growing body parts in a lab and transplanting them into people, this time with nostrils and vaginas. Martin Birchall, of The Ear Institute at University College London, who co-authored an accompanying commentary.

  • *Biotech indexes have worst day since August 2011. *Bed, Bath& Beyond slumps after earnings. NEW YORK, April 10- U.S. stocks sank on Thursday, with the S&P 500 turning negative for the year and the Nasdaq falling its most in a day since June 2012 as investors again sold high-flying names in the technology and biotech sectors and sought shelter in defensive names.

  • Pfizer CEO worries about ACA coverage     Thursday, 10 Apr 2014 | 11:43 AM ET

    Ian Read, Pfizer CEO, discusses the pricing and affordability of drugs in the U.S. Read also weighs in on insurance coverage under the Affordable Care Act.

  • CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.

  • Eli Lilly CEO: We keep investing in R&D     Thursday, 10 Apr 2014 | 6:51 AM ET

    John Lechleiter, Chairman, President & CEO of Eli Lilly, discusses the company's growth plans as products come off patent and consumers move to generic drugs.

  • The biotech parade     Wednesday, 9 Apr 2014 | 12:27 PM ET

    CNBC's Meg Tirrell provides insight on the increase in biotech IPOs, and what to expect from both Cerulean Pharma & Adamas Pharmaceuticals ahead of their IPO pricing Wednesday night.

  • There’s still value in biotech stocks: Citi pro Monday, 7 Apr 2014 | 6:23 PM ET

    Despite the recent meltdown in biotech, there are still areas of opportunity within the sector, Citi's Yaron Werber says.

  • Diversifying your pharma portfolio     Monday, 7 Apr 2014 | 1:07 PM ET

    Mallinckrodt is buying drug maker Questcor for $5.6 billion. Barbara Ryan, FTI Consulting managing director, discusses consolidation in pharmaceuticals and shares what stocks she likes in the space.

  • CNBC's Seema Mody and Dominic Chu look at what's behind today's massive market sell off including biotechs and online retailers.

  • Heather Bresch Mylan CEO, discusses the concern over capping drug prices and the impact of Obamacare on rising drug costs.

  • Why investors should be exposed to biotech     Monday, 31 Mar 2014 | 5:30 AM ET

    Jason Kolbert, head of health care research at Maxim Group, says that last week's biotech sell-off was not justified as the sector is going through a "paradigm shift" which should results in higher valuations.

  • Max Herrmann, partner and healthcare research analyst at Oriel Securities, said biotech stocks have gone through a correction after a "phenomenal" rally.

Most Popular Video

Wednesday, 23 Apr 2014 | 10:50 PM ET

Taro Kono, Member of the House of Representatives in Japan's Parliament, says the Liberal Democratic Party (LDP) stands behind Prime Minister Shinzo Abe in pushing for the TPP trade deal.

Wednesday, 23 Apr 2014 | 10:34 PM ET

Charles Li, Chief Executive of Hong Kong Exchanges and Clearing, says the launch of a new commodity trading platform for three metal contracts will facilitate long-term cross-border investments.

Wednesday, 23 Apr 2014 | 10:16 PM ET

David Garrity, Principal at GVA Research, says Apple's decision to raise its dividend and step up its stock buyback program signaled confidence in the tech giant's outlook.